3rd Quarter - Report
BECTON, DICKINSON AND COMPANY for BECTON DICKINSON AND COMPANY
Client
Income
—
Expenses
$110,000
Expense method
C: businesses, Internal Revenue Code section 162(e)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S.959, Pharmaceutical Compounding Quality and Accountability Act, Issues related to drug compounding FDA regulation of diagnostic tests
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
| ELIZABETH WOODY | — |
Medicare/Medicaid MMM
Reimbursement for diagnostic tests
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
| ELIZABETH WOODY | — |
Taxation/Internal Revenue Code TAX
H.R.523, Protect Medical Innovation Act of 2013 Corporate tax issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
| ELIZABETH WOODY | — |
Budget/Appropriations BUD
NIH Funding FDA Funding PEPFAR Funding
| Lobbyist | Covered position, as disclosed |
|---|---|
| JENNIFER M LURAY | — |
| DANNY LY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.